Korean J Urol.  2014 Feb;55(2):112-119. 10.4111/kju.2014.55.2.112.

The Efficacy and Safety of Tadalafil 5 mg Once Daily in the Treatment of Erectile Dysfunction After Robot-Assisted Laparoscopic Radical Prostatectomy: 1-Year Follow-up

• Seo YE
• Kim SD
• Kim TH
• Sung GT

• KMID: 1988436
• DOI: http://doi.org/10.4111/kju.2014.55.2.112

Abstract

PURPOSE
To evaluate the efficacy and safety of tadalafil 5 mg once daily use in the treatment of erectile dysfunction (ED) after robot-assisted laparoscopic radical prostatectomy (RALP).
MATERIALS AND METHODS
The study retrospectively evaluated 92 patients who underwent RALP at Dong-A University Hospital. The patients were surveyed by use of the abridged five-item version of the International Index of Erectile Function (IIEF-5) questionnaire, which was self-administered before surgery and at 6 months and 1 year after surgery. The 92 patients were classified into the tadalafil group (n=47) and the non-tadalafil group (n=45). Each group was then classified depending on the nerve-sparing (NS) procedure used: bilateral NS or unilateral NS.
RESULTS
At 6 months, the total IIEF-5 scores of the tadalafil group and the non-tadalafil group were 10.0+/-3.4 and 7.0+/-4.0, respectively. At 1 year, the total IIEF-5 score in the tadalafil group was significantly greater than that in the non-tadalafil group (13.2+/-5.6 vs. 7.7+/-4.8, p<0.0001). Statistically significant improvements (p<0.05) were observed in the tadalafil group for all 5 domains of the IIEF-5 score, whereas in the non-tadalafil group there was no significant improvement in any of the domains at 1 year. The reported side effects were flushing (8.5%, n=4), headache (4.3%, n=2), and dizziness (2.1%, n=1).
CONCLUSIONS
In ED patients after NS RALP, a once-daily dose of tadalafil 5 mg was well tolerated and significantly improved EF compared with that in the non-tadalafil group.

Keyword

Erectile dysfunction; Once daily; Prostatectomy; Robotics; Tadalafil

MeSH Terms

Dizziness
Erectile Dysfunction*
Flushing
Follow-Up Studies*
Headache
Humans
Male
Prostatectomy*
Questionnaires
Retrospective Studies
Robotics

Figure

• 

  FIG. 1 Positive responders to tadalafil following robot-assisted laparoscopic radical prostatectomy. (A) The positive responders to tadalafil with time and patients at risk determined by the Kaplan-Meier method. There was statistically significant difference between 2 subgroups (log-rank test p=0.0049). (B) The positive responders to tadalafil with time and patients at risk determined by the Kaplan-Meier method. There was statistically significant difference between 4 subgroups (log-rank test p=0.0098).

• 

  FIG. 2 Comparision of total IIEF-5 scores between nerve-sparing groups following robot-assisted laparoscopic radical prostatectomy. (A) Mean±SEM plot of total IIEF-5 score across 2 subgroups. (B) Mean±SEM plot of total IIEF-5 score across 4 subgroups. IIEF-5, the abridged five-item version of the International Index of Erectile Function Questionnaire; SEM, standard error of measurements.

Reference

1. Zippe CD, Pahlajani G. Penile rehabilitation following radical prostatectomy: role of early intervention and chronic therapy. Urol Clin North Am. 2007; 34:601–618.

2. Raina R, Lakin MM, Agarwal A, Sharma R, Goyal KK, Montague DK, et al. Long-term effect of sildenafil citrate on erectile dysfunction after radical prostatectomy: 3-year follow-up. Urology. 2003; 62:110–115.

3. Salonia A, Burnett AL, Graefen M, Hatzimouratidis K, Montorsi F, Mulhall JP, et al. Prevention and management of postprostatectomy sexual dysfunctions part 2: recovery and preservation of erectile function, sexual desire, and orgasmic function. Eur Urol. 2012; 62:273–286.

4. Stephenson RA. Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database. Urol Clin North Am. 2002; 29:173–181.

5. Greene KL, Cowan JE, Cooperberg MR, Meng MV, DuChane J, Carroll PR, et al. Who is the average patient presenting with prostate cancer? Urology. 2005; 66:5 Suppl. 76–82.

6. Defade BP, Carson CC 3rd, Kennelly MJ. Postprostatectomy erectile dysfunction: the role of penile rehabilitation. Rev Urol. 2011; 13:6–13.

7. Moreland RB, Goldstein I, Traish A. Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells. Life Sci. 1998; 62:PL 309–PL 318.

8. Megas G, Papadopoulos G, Stathouros G, Moschonas D, Gkialas I, Ntoumas K. Comparison of efficacy and satisfaction profile, between penile prosthesis implantation and oral PDE5 inhibitor tadalafil therapy, in men with nerve-sparing radical prostatectomy erectile dysfunction. BJU Int. 2013; 112:E169–E176.

9. Hatzimouratidis K, Burnett AL, Hatzichristou D, McCullough AR, Montorsi F, Mulhall JP. Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical application. Eur Urol. 2009; 55:334–347.

10. Lee J. Penile rehabilitation should not be the norm for patients post-radical prostatectomy. Can Urol Assoc J. 2009; 3:54–56.

11. Montorsi F, Guazzoni G, Strambi LF, Da Pozzo LF, Nava L, Barbieri L, et al. Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial. J Urol. 1997; 158:1408–1410.

12. McMahon C. Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J Sex Med. 2005; 2:415–425.

13. Mulhall JP, Morgentaler A. Penile rehabilitation should become the norm for radical prostatectomy patients. J Sex Med. 2007; 4:538–543.

14. Kong GS, Seong YK, Sung GT. Robotic-assisted radical prostatectomy using da VinciTM surgical robotic system: initial Korean experience. Korean J Urol. 2005; 46:353–359.

15. You YC, Kim TH, Sung GT. Effect of bladder neck preservation and posterior urethral reconstruction during robot-assisted laparoscopic radical prostatectomy for urinary continence. Korean J Urol. 2012; 53:29–33.

16. Zippe CD, Jhaveri FM, Klein EA, Kedia S, Pasqualotto FF, Kedia A, et al. Role of Viagra after radical prostatectomy. Urology. 2000; 55:241–245.

17. Montorsi F, Aversa A, Moncada I, Perimenis P, Porst H, Barker C, et al. A randomized, double-blind, placebo-controlled, parallel study to assess the efficacy and safety of once-a-day tadalafil in men with erectile dysfunction who are naïve to PDE5 inhibitors. J Sex Med. 2011; 8:2617–2624.

18. Padma-Nathan H, McCullough AR, Levine LA, Lipshultz LI, Siegel R, Montorsi F, et al. Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int J Impot Res. 2008; 20:479–486.

19. Montorsi F, Brock G, Lee J, Shapiro J, Van Poppel H, Graefen M, et al. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol. 2008; 54:924–931.

20. Zagaja GP, Mhoon DA, Aikens JE, Brendler CB. Sildenafil in the treatment of erectile dysfunction after radical prostatectomy. Urology. 2000; 56:631–634.

21. Lue TF. Erectile dysfunction. N Engl J Med. 2000; 342:1802–1813.

22. Mydlo JH, Viterbo R, Crispen P. Use of combined intracorporal injection and a phosphodiesterase-5 inhibitor therapy for men with a suboptimal response to sildenafil and/or vardenafil monotherapy after radical retropubic prostatectomy. BJU Int. 2005; 95:843–846.

23. Lagoda G, Jin L, Lehrfeld TJ, Liu T, Burnett AL. FK506 and sildenafil promote erectile function recovery after cavernous nerve injury through antioxidative mechanisms. J Sex Med. 2007; 4(4 Pt 1):908–916.

24. Lagoda G, Sezen SF, Liu T, Hoke A, Burnett AL. FK506-binding protein localizations in human penile innervation. BJU Int. 2008; 101:604–609.

25. Yuan J, Zhang R, Yang Z, Lee J, Liu Y, Tian J, et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol. 2013; 63:902–912.

26. Porst H, Rajfer J, Casabe A, Feldman R, Ralph D, Vieiralves LF, et al. Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction. J Sex Med. 2008; 5:2160–2169.

27. Porst H, Giuliano F, Glina S, Ralph D, Casabe AR, Elion-Mboussa A, et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol. 2006; 50:351–359.

28. Hanson-Divers C, Jackson SE, Lue TF, Crawford SY, Rosen RC. Health outcomes variables important to patients in the treatment of erectile dysfunction. J Urol. 1998; 159:1541–1547.

29. Kang DH, Lee JY, Park SY, Moon HS, Jeong TY, Yoo TK, et al. Efficacy and safety of tadalafil 5 mg administered once daily in Korean men with erectile dysfunction: a prospective, multicenter study. Korean J Urol. 2010; 51:647–652.